Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
Key Highlights
- ➤120 participants randomized across five U.S. clinical sites
- ➤NASARIX study enrollment completed after screening 144 individuals
- ➤Study compares NASARIX with saline control in adults with allergic rhinitis
- ➤Company expects data review and clinical readout after treatment and follow-up
Expert Statements
Tomer Izraeli, Chief Executive Officer of Polyrizon
“Completing enrollment and randomization of all 120 participants represents an important milestone in the clinical development of NASARIX”
Tomer Izraeli, Chief Executive Officer of Polyrizon
“With enrollment now complete across five U.S. clinical sites, we are focused on completing the remaining study activities and advancing toward the clinical data readout.”
Tomer Izraeli, Chief Executive Officer of Polyrizon
“We believe that this achievement marks another important step in our efforts to bring our innovative nasal barrier technology closer to patients.”
All 120 planned participants randomized across five clinical sites in the United States
Raanana, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful completion of patient enrollment and randomization in its U.S. multicenter clinical study evaluating NASARIX, the Company's proprietary investigational nasal hydrogel product candidate designed to provide protection against airborne allergens.
Get started
Create a free account to read the full story.